Medidata Solutions (NASDAQ:MDSO) was downgraded by analysts at TheStreet from a “b” rating to a “c+” rating in a research report issued on Thursday.

A number of other equities analysts also recently commented on the stock. Wells Fargo & Company reduced their price objective on shares of Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating for the company in a research note on Friday, October 27th. Zacks Investment Research upgraded shares of Medidata Solutions from a “sell” rating to a “hold” rating in a research note on Friday, November 10th. SunTrust Banks restated a “buy” rating and set a $92.00 price objective on shares of Medidata Solutions in a research note on Friday, October 27th. Royal Bank of Canada restated a “hold” rating and set a $80.00 price objective on shares of Medidata Solutions in a research note on Friday, October 27th. Finally, KeyCorp restated a “buy” rating and set a $86.00 price objective on shares of Medidata Solutions in a research note on Sunday, September 17th. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $84.54.

Medidata Solutions (NASDAQ:MDSO) opened at $66.64 on Thursday. The firm has a market cap of $3,762.55, a price-to-earnings ratio of 77.54, a P/E/G ratio of 3.99 and a beta of 1.69. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.29 and a quick ratio of 3.37. Medidata Solutions has a one year low of $47.77 and a one year high of $85.92.

Medidata Solutions (NASDAQ:MDSO) last announced its earnings results on Thursday, October 26th. The company reported $0.33 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.02. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The firm had revenue of $140.08 million during the quarter, compared to analyst estimates of $141.27 million. During the same period in the prior year, the business earned $0.28 EPS. The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. analysts predict that Medidata Solutions will post 0.78 earnings per share for the current year.

In other news, CFO Rouven Bergmann sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $65.40, for a total transaction of $130,800.00. Following the transaction, the chief financial officer now directly owns 91,775 shares of the company’s stock, valued at $6,002,085. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Tarek Sherif sold 200,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $68.76, for a total transaction of $13,752,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 237,010 shares of company stock worth $16,305,136. Insiders own 5.80% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in MDSO. Canada Pension Plan Investment Board increased its holdings in shares of Medidata Solutions by 2,994.6% during the third quarter. Canada Pension Plan Investment Board now owns 1,151,200 shares of the company’s stock worth $89,863,000 after purchasing an additional 1,114,000 shares during the period. American Century Companies Inc. increased its holdings in shares of Medidata Solutions by 610.9% during the third quarter. American Century Companies Inc. now owns 1,186,843 shares of the company’s stock worth $92,645,000 after purchasing an additional 1,019,883 shares during the period. Eagle Asset Management Inc. increased its stake in Medidata Solutions by 292.9% in the third quarter. Eagle Asset Management Inc. now owns 835,286 shares of the company’s stock valued at $66,371,000 after acquiring an additional 622,694 shares during the last quarter. State Street Corp increased its stake in Medidata Solutions by 27.7% in the second quarter. State Street Corp now owns 1,828,913 shares of the company’s stock valued at $143,022,000 after acquiring an additional 396,793 shares during the last quarter. Finally, Voya Investment Management LLC increased its stake in Medidata Solutions by 1,571.0% in the second quarter. Voya Investment Management LLC now owns 376,259 shares of the company’s stock valued at $29,423,000 after acquiring an additional 353,742 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Medidata Solutions (MDSO) Cut to “C+” at TheStreet” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/16/medidata-solutions-mdso-cut-to-c-at-thestreet.html.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.